Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSL ( (AU:CSL) ) has shared an announcement.
CSL Limited has notified the market of the cessation of 48,090 rights (CSLAL) on the ASX, following the lapse of conditional rights to securities after the relevant conditions were not met or became incapable of being satisfied as of 13 March 2026. The change slightly adjusts CSL’s issued capital structure, signalling a routine clean-up of unvested equity rights rather than an issuance of new securities, with limited immediate impact on existing shareholders but incremental clarity on the company’s outstanding equity-based instruments.
The most recent analyst rating on (AU:CSL) stock is a Hold with a A$155.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a global biotechnology company listed on the ASX, focused on developing and manufacturing biopharmaceutical products, including vaccines, plasma therapies and specialty medicines. It serves healthcare markets worldwide, supplying treatments for serious and rare diseases and maintaining a significant presence in the Australian and international life sciences sectors.
Average Trading Volume: 1,169,650
Technical Sentiment Signal: Sell
Current Market Cap: A$68.26B
Find detailed analytics on CSL stock on TipRanks’ Stock Analysis page.